New GLP-1 oral pill lowers blood sugar and reduces bodyweight, clinical trial finds

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight. At the American Diabetes Association's Scientific Session, Mass General Brigham physician investigator Vanita Aroda, MD, presented findings from SOLSTICE, a Phase IIb randomized, placebo-controlled clinical trial that tested the oral GLP-1 RA known as elecoglipron.